

# Clinical trials of rivaroxaban 20mg

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
<b>rivaroxaban 20mg vs placebo</b>			
<a href="#">EISNTEIN EXT , 2010</a> n=602/595 follow-up:	rivaroxaban alone (20 mg once daily)for an additional 6 or 12 months versus placebo	patients who had completed 6 to 12 months of treatment for venous thromboembolism	
<b>rivaroxaban 20mg vs aspirin</b>			
<a href="#">EINSTEIN CHOICE (20mg) , 2017</a> [NCT02064439] n=1107/1131 follow-up:	Rivaroxaban 20 mg once daily for 12 months versus ASA (Acetylsalicylic Acid) 100 mg once daily for 12 months	Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation	

More details and results :

- direct oral anticoagulant (DAO) for venous thrombosis in all types of patients at <http://www.trialresultscenter.org/go-Q505>
- antithrombotics for venous thrombosis in secondary prevention - 2 at <http://www.trialresultscenter.org/go-Q682>

## References

### **EISNTEIN EXT, 2010:**

Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510 [21128814] [10.1056/NEJMoa1007903](https://doi.org/10.1056/NEJMoa1007903)

### **EINSTEIN CHOICE (20mg), 2017:**

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N. Engl. J. Med. 2017; 376:1211-1222 [28316279] [10.1056/NEJMoa1700518](https://doi.org/10.1056/NEJMoa1700518)